Moreover, CSO treatment could alleviate neuroinflammation by inhibiting Toll‐like receptor 4 (TLR4)‐nuclear factor kappa B (NF‐κB) pathway and the over‐activation of microglia and astrocyte (Liu et al., 2020). The gene discussed is TLR4; the disease is craniosynostosis.